Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
An ongoing dialogue on HIV/AIDS, infectious diseases,
July 1st, 2012
“HAART Era” Now Longer Than “Pre-HAART Era” — Can We Officially Retire “HAART”?
As I’ve shared before, I’m no fan of the term “HAART” and do everything I can to stop people from using it.
(I’m a fun guy to have at parties.)
I’m returning to this pet peeve of mine because I realized recently that we’ve passed a milestone of sorts:
- Period of no effective HIV treatment, 15 years (1981-1996)
- Period of effective HIV treatment, 16 years (1996-2012)
I came to this realization while reviewing a manuscript on an HIV-related complication. The author repeatedly (and at great length) described how this complication had changed with the “advent of HAART” (cringe) –incidence down, prognosis better, management altered. There were many comparisons between the “pre-HAART era” and the “post-HAART era”, even a separate table on the differences.
Of historical interest, yes, but hardly earth-shattering news at this point , and not of much practical use to the reader –pretty much everything changed with effective HIV treatment.
The bottom line is that HIV-related complications should be considered now only in the context of patients who are receiving, or who are about to receive, antiretroviral therapy. In other words, describing how to manage HIV-related complications without HIV treatment would be like an endocrinologist describing management of Type 1 diabetes complications without insulin.
So since HIV treatment is now the new normal — becoming more so with each passing year — let’s just call it antiretroviral therapy, and assume that it’s standard of care to give the highly active kind.
And if you want to abbreviate it, “ART” will do just fine.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
- Ebola Vaccine, a New Use for Listerine, USPSTF on HSV, Nether Grooming, and More: A Christmas and Hanukkah Overlap ID Link-o-Rama
- Top Stories in HIV Medicine for 2016
- Poll: Should Medicine and Family Practice Residency Programs Have a Dedicated HIV Track?
- Holiday Distractions, Dirty Pets, and Time to Vote for Your Favorite Cartoon Caption
- Two Case Reports Worth Reading, and Enlisting Pro-Vaccine Support
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Mystifying Abbreviations on Daily Medical Rounds (46)
- ID Cartoon Caption Contest #1 Winner — and a New Contest for the End of Summer (46)
- Should Doctors Still Be Allowed to Wear White Coats? You Decide (43)
Subscribe to HIV and ID Observations via Email
- Bacterial DNA Level Might Predict Infection in Patients with Alcoholic Hepatitis
- Pinning Down Risk for Zika-Linked Birth Defects (FREE)
- A Blood Test for Variant Creutzfeldt-Jakob Disease?
- Antiretroviral Therapy and Life Expectancy in Rural South Africa
- Infectious Diseases Consultation Associated with Improved Cryptococcal Infection Outcome
Physician's First WatchToday's breaking medical news
- Abacavir AIDS aids clinical care antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff CROI cure darunavir dolutegravir efavirenz elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID Learning Unit IDSA Infectious Diseases influenza Link-o-Rama lyme disease Massachusetts MRSA Patient Care PEP Policy PrEP prevention primary care raltegravir resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir vaccination